Research & Development: MP0250: Phase 2 in multiple myeloma: First patients expected in the coming months. Full regulatory approvals received for Germany, approvals in Poland and Italy expected in the coming weeks MP0250: Additional Phase 2 trial for solid tumor indication to be submitted in 2017;

Zurich-Schlieren, April 13, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today published the Invitation to the Annual General Meeting 2017. The Annual General Meeting will be held on

Zurich-Schlieren, April 12, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin®* therapies, today announces that Christian Zahnd,  co-founder and former CEO of the company, has decided not to stand for re-election as

Long-term venture capital investors holding reduced to 28% of share capital Private investors acquired shares from venture capitalist investors in secondary block trades Zurich-Schlieren, April 6, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is

Zurich-Schlieren, March 31, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today published its audited Financial Results for 2016 and the company’s 2016 Annual Report.

Zurich-Schlieren, March 01, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that it will present at at the Cowen and Company 37th Annual Healthcare Conference on Tuesday, March 07, 2017

Research & Development: MP0250: Phase 2 in multiple myeloma: study approved by BfArM in Germany and ongoing regulatory submissions in other countries; first safety data expected in 2017 and efficacy data in 2018 MP0250: Additional Phase 2 trial for solid tumor indication to be submitted in 2017;

Zurich-Schlieren, February 9, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin®* therapies, today announces that the Board of Directors has decided to propose Gwen Fyfe, MD, for election as member of the Board of

Zurich-Schlieren, January 04, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at